

## Hadron Systems Discussion

Recent findings at the University of Cambridge provide further evidence of tumor-associated adaptive stromal cells insulating tumors from recognition by the immune system. Studies at the Wistar Institute, the Ludwig Institute for Cancer Research, and Harvard Medical School, among other institutions, are conclusive that stromal cells of the tumor microenvironment are tumorigenic and metastatic.

Results of promising vaccines, inhibiting tumor-associated cells, are an immediate halt to the progression of a cancer, significant loss of viable tumor cells, and diminishment of tumor angiogenic vessels.

The combination product of Hadron Systems is based on the principles of ablation of cells of the tumor microenvironment, accomplishing that goal through isotopically labeled peptide constructs targeting and nuclei localization in combination with an external source of particles, noting the very rapid growth and profitability of proton therapy. A vaccine takes an average of 8 years to develop at the cost of hundreds of millions of dollars, while clinical inauguration of hadronimmunotherapy is expected in September 2012.